Pharmaceuticals
Cable admits Pfizer-AstaraZeneca deal involves ‘national interest’ issues
05 May 2014
Britain’s Business Secretary Vince Cable said late on Sunday that the bid by Pfizer Inc for AstraZeneca Plc raised questions of “overriding national interest”, as the opposition Labour Party stepped up its campaign against the proposed takeover
AstraZeneca rejects Pfizer’s revised $106 billion offer
02 May 2014
Today’s 50 pounds ($84.47) a share indicative offer followed AstraZeneca's decision to reject an earlier proposal that valued it at 46.61 pounds per share
AstraZeneca to consider Pfizer’s $106-bn bid
02 May 2014
The announcement comes just days after AstraZeneca Plc denied plans to discuss any partnership proposals with Pfizer
Bayer offers to swap cash and animal health unit for Merck's consumer healthcare
30 Apr 2014
German healthcare major Bayer AG has offered to swap its animal health unit and also pay some cash in exchange for Merck & Co's consumer healthcare business
HC blocks Ranbaxy-Sun Pharma merger over insider trading allegations
30 Apr 2014
The order was in response to a petition for a Sebi inquiry into possible insider trading in Ranbaxy shares that saw heavy trading before the merger with Sun Pharma was announced
Reckitt Benckiser confirms bidding for Merck & Co's consumer health business
29 Apr 2014
British consumer goods company Reckitt Benckiser has emerged as a front runner in the auction, although Bayer AG, Novartis, and Procter & Gamble Co are also in the race
Pfizer confirms AstraZeneca's rejection; to explore options
28 Apr 2014
US drugs giant Pfizer today confirmed that it had made a $98.67 billion (£58.73 billion) takeover offer for AstraZeneca, which was rejected by the UK-based company
Forest Labs to buy GI specialist Furiex in $1.46-bn deal
28 Apr 2014
Forest, which itself is in the process of being acquired by Actavis Plc for $25 billion, said that Actavis supported the deal
Greater investment needed to check malaria: WHO
25 Apr 2014
Britain’s Shire Plc recently rejected Allergan’s takeover approach: report
25 Apr 2014
Shire, the UK's third-biggest drug maker with a market cap of $33 billion, is itself an aggressive acquirer, having made 15 acquisitions since 2000
Valeant tables hostile $45.7 bn bid for Botox maker Allergan
23 Apr 2014
Valeant Pharmaceuticals International Inc, Canada's biggest drug maker and one of the most aggressive acquirers, yesterday tabled a hostile $45.7-billion cash and stock bid for Botox maker Allergan Inc
Novartis AG, GSK in $23-bn assets swap deal
22 Apr 2014
Swiss drug giant Novartis AG and Britain's GlaxoSmithKline Plc (GSK) today announced a swap of assets in a deal valued at around $23 billion
Eli Lilly to buy Novartis AG's animal health business for $5.4 bn
22 Apr 2014
Eli Lilly and Co today struck a deal to buy Swiss drugmaker Novartis AG's animal health business for $5.4 billion in cash in order to strengthen and diversify its own animal health business, Elanco.
Valeant teams up with hedge fund to buy Botox maker Allergan for $42 bn
22 Apr 2014
News of the impending bid sent the stock price of Valeant and Allergan companies soaring in after-hours trading
Pfizer weighs $101-bn bid for AstraZeneca
21 Apr 2014
A potential deal with AstraZeneca would be the biggest-ever acquisition in the pharmaceutical industry, and would see another iconic British brand being acquired by a foreign company
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "CBDT explains Budget proposal on capital gains tax")
.jpg "Economic Survey projects India’s GDP growth at 6.5–7% in 2024-25")
.jpg "Adani-Sirus joint venture to acquire 77.5% stake in Coredge.io parent Parserlabs")
